Baxter (NYSE:BAX) and Biomérieux (EPA:BIM) today announced CE mark approval for the Nephroclear CCL14 test.
The companies designed the Nephroclear CCL14 test to predict persistent severe acute kidney injury (PS-AKI) and it can be used to support timely clinical decision-making and care pathways, according to a news release.
Baxter and Biomérieux plan to launch Nephroclear CCL 14 commercially across western Europe in 2022.
“Baxter is proud to partner with Biomérieux to offer the Nephroclear CCL14 test as an important new diagnostic option to support individualized AKI management that gives every patient the greatest opportunity for recovery,” GM of Baxter’s acute therapies business Reaz Rasul said in the release. “We remain committed to advancing purposeful innovation across the care continuum to help reduce complexity and enable efficiencies in critical care, especially as hospitals continue to feel the impact of the COVID-19 pandemic.”
The …